"Singapore-based biotech firm Tychan Pte Ltd has started human clinical trials for a potential COVID-19 treatment known as TY027. From concept to clinical trials, the process took less than four months.
Directly developed as a COVID-19 treatment, TY027 is also being explored for its potential to prevent infection — a crucial application for the safe re-opening of economies and businesses."